Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,otherCurrentLiab,depreciation,changeToNetincome,changeToLiabilities,totalCashFromOperatingActivities,changeInCash,changeToOperatingActivities,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,IVIXF,574220.0,5538039808,,,-425809,,-425809,520671,224512,-470493,-470493,,,,,,0,622161,1092654,397649,44684,,-425809,-425809,4702500.0,280260.0,5276720.0,5556980.0,130939698.0,-127963329.0,2300351.0,521075.0,280260.0,2300351.0,2270.0,852210.0,215983.0,55220.0,,69561.0,307365.0,0.0,-48884.0,-48884.0,,,571950.0,en-US,US,EQUITY,False,Delayed Quote,0.0092,1628609069,0.0,0.0099,0.0092,0.0092,3000,USD,PNK,19913032,-14400000,False,False,PRE,4,0.0,0.0092 - 0.0092,us_market,0,INVION LTD,0.0092,finmb_28625535,Other OTC,Invion Limited,AUD,562,0,0.0051,1.2439024,0.0041 - 0.0185,-0.0093,-0.5027027,0.0041,0.0185,0.009698056,-0.0004980555,-0.05135622,0.009890352,-0.0006903522,-0.06980056,15,America/New_York,EDT,1.66,,,0.0185,0.0041,0.0097,0.0099,562,,5.54B,,2.19B,87.98%,0.00%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",-21.82%,-27.34%,-8.69%,-11.97%,2.87M,0.00,-32.90%,1.92M,-505.42k,-625.38k,,,521.08k,0,,,3.04,,402.05k,54.76k,Value,3102,Healthcare,"Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.",Melbourne,61 3 8618 6843,VIC,1609372800,Australia,http://www.inviongroup.com,86400,692 High Street,Drug Manufacturers—Specialty & Generic,East Kew
t-1,IVIXF,574220.0,5538039808,,,-425809,,-425809,520671,224512,-470493,-470493,,,,,,0,622161,1092654,397649,44684,,-425809,-425809,4702500.0,280260.0,5276720.0,5556980.0,130939698.0,-127963329.0,2300351.0,521075.0,280260.0,2300351.0,2270.0,852210.0,215983.0,55220.0,,69561.0,307365.0,0.0,-48884.0,-48884.0,,,571950.0,en-US,US,EQUITY,False,Delayed Quote,0.0092,1628609069,0.0,0.0099,0.0092,0.0092,3000,USD,PNK,19913032,-14400000,False,False,PRE,4,0.0,0.0092 - 0.0092,us_market,0,INVION LTD,0.0092,finmb_28625535,Other OTC,Invion Limited,AUD,562,0,0.0051,1.2439024,0.0041 - 0.0185,-0.0093,-0.5027027,0.0041,0.0185,0.009698056,-0.0004980555,-0.05135622,0.009890352,-0.0006903522,-0.06980056,15,America/New_York,EDT,1.66,,,0.0185,0.0041,0.0097,0.0099,562,,5.54B,,2.19B,87.98%,0.00%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",-21.82%,-27.34%,-8.69%,-11.97%,2.87M,0.00,-32.90%,1.92M,-505.42k,-625.38k,,,521.08k,0,,,3.04,,402.05k,54.76k,Value,3102,Healthcare,"Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.",Melbourne,61 3 8618 6843,VIC,1609372800,Australia,http://www.inviongroup.com,86400,692 High Street,Drug Manufacturers—Specialty & Generic,East Kew
t-2,IVIXF,593930.0,5538039808,,,113118,,113118,388029,552031,78666,78666,,,,,,0,810976,732310,258944,34451,,113118,113118,4840000.0,326822.0,5433930.0,5760752.0,130555435.0,-127111711.0,1990206.0,618843.0,326822.0,1990206.0,3891.0,916861.0,271845.0,105670.0,11000.0,69559.0,270752.0,-151427.0,249908.0,249908.0,-14892.0,-37202.0,590039.0,en-US,US,EQUITY,False,Delayed Quote,0.0092,1628609069,0.0,0.0099,0.0092,0.0092,3000,USD,PNK,19913032,-14400000,False,False,PRE,4,0.0,0.0092 - 0.0092,us_market,0,INVION LTD,0.0092,finmb_28625535,Other OTC,Invion Limited,AUD,562,0,0.0051,1.2439024,0.0041 - 0.0185,-0.0093,-0.5027027,0.0041,0.0185,0.009698056,-0.0004980555,-0.05135622,0.009890352,-0.0006903522,-0.06980056,15,America/New_York,EDT,1.66,,,0.0185,0.0041,0.0097,0.0099,562,,5.54B,,2.19B,87.98%,0.00%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",-21.82%,-27.34%,-8.69%,-11.97%,2.87M,0.00,-32.90%,1.92M,-505.42k,-625.38k,,,521.08k,0,,,3.04,,402.05k,54.76k,Value,3102,Healthcare,"Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.",Melbourne,61 3 8618 6843,VIC,1609372800,Australia,http://www.inviongroup.com,86400,692 High Street,Drug Manufacturers—Specialty & Generic,East Kew
t-3,IVIXF,593930.0,5538039808,,,113118,,113118,388029,552031,78666,78666,,,,,,0,810976,732310,258944,34451,,113118,113118,4840000.0,326822.0,5433930.0,5760752.0,130555435.0,-127111711.0,1990206.0,618843.0,326822.0,1990206.0,3891.0,916861.0,271845.0,105670.0,11000.0,69559.0,270752.0,-151427.0,249908.0,249908.0,-14892.0,-37202.0,590039.0,en-US,US,EQUITY,False,Delayed Quote,0.0092,1628609069,0.0,0.0099,0.0092,0.0092,3000,USD,PNK,19913032,-14400000,False,False,PRE,4,0.0,0.0092 - 0.0092,us_market,0,INVION LTD,0.0092,finmb_28625535,Other OTC,Invion Limited,AUD,562,0,0.0051,1.2439024,0.0041 - 0.0185,-0.0093,-0.5027027,0.0041,0.0185,0.009698056,-0.0004980555,-0.05135622,0.009890352,-0.0006903522,-0.06980056,15,America/New_York,EDT,1.66,,,0.0185,0.0041,0.0097,0.0099,562,,5.54B,,2.19B,87.98%,0.00%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",-21.82%,-27.34%,-8.69%,-11.97%,2.87M,0.00,-32.90%,1.92M,-505.42k,-625.38k,,,521.08k,0,,,3.04,,402.05k,54.76k,Value,3102,Healthcare,"Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.",Melbourne,61 3 8618 6843,VIC,1609372800,Australia,http://www.inviongroup.com,86400,692 High Street,Drug Manufacturers—Specialty & Generic,East Kew
